Synergistic Compounds

What "synergy" means here

In pharmacology, synergy has a narrow meaning: two things together do more than the sum of what each does alone. Most claims about fat-loss "stacks" never get tested against that bar. A more useful question is simpler. Has the combination been studied in people, compared with each part on its own, with body composition measured?

By that standard, medicines that hit more than one hormone receptor, tested in large randomized trials, sit at the top. Trials pairing a GLP-1 drug with exercise or with a muscle-protecting drug come next. Combinations people assemble from research-use vials sit at the bottom, because no trial has examined them.

Our page on exercise and peptide synergy goes deeper on training. The fat-loss and metabolic peptides hub covers the individual compounds.

Combination drugs: the clearest human evidence

The strongest evidence comes from companies that built a combination into one product and tested it against a single-mechanism drug.

Tirzepatide (sold as Zepbound and Mounjaro) is one molecule that activates both the GIP and GLP-1 receptors. In SURMOUNT-5, an open-label Phase 3b trial in adults with obesity, people on tirzepatide lost an average of 20.2% of body weight at 72 weeks, compared with 13.7% on semaglutide (Wegovy), which acts on GLP-1 receptors only. That is about as direct a human test of "two mechanisms beat one" as exists. Both are prescription medicines approved by the FDA for weight management.

CagriSema pairs semaglutide with cagrilintide, a long-acting amylin analog. Its Phase 3 trials used a fixed weekly dose of 2.4 mg of each. REDEFINE 1 (68 weeks, 3,417 adults, all given lifestyle counseling) was designed to separate the parts. Counting everyone regardless of whether they stayed on treatment, the combination produced 20.4% average weight loss versus 3.0% on placebo. Novo Nordisk reported 14.9% for semaglutide alone and 11.5% for cagrilintide alone. The combination beat either part alone, though by less than the two effects added together.

Beating its own components isn't the same as beating everything. In REDEFINE 4, an 84-week open-label trial of 809 adults, CagriSema produced 23.0% weight loss against 25.5% for tirzepatide 15 mg weekly (if everyone had stayed on treatment) and missed its goal of showing non-inferiority. As of October 2026, CagriSema is under FDA review, with a decision expected late in 2026, and isn't approved anywhere. Our cagrilintide profile has the trial details.

Retatrutide adds glucagon receptors as a third target. As of October 2026 it has five positive Phase 3 readouts. In TRIUMPH-2 (adults with obesity and type 2 diabetes, 80 weeks), participants started at 2 mg weekly and stepped up every four weeks to a target dose. Those assigned to 12 mg lost an average of 20.8% of body weight; the 4 mg group lost 12.7%. In TRIUMPH-3, which enrolled people with severe obesity and heart disease, losses reached 22.6%. Dysesthesia (abnormal skin sensations such as tingling) affected 4.5-7.3% of retatrutide participants in TRIUMPH-2 versus 0.7% on placebo. Retatrutide isn't approved; Lilly plans to submit it to the FDA in the first quarter of 2027. The retatrutide profile covers the full program.

These trials show something narrow but real: acting on more than one appetite pathway at once can add weight loss beyond a GLP-1 drug alone. They say nothing about research-use vials, which aren't the products tested.

Exercise, protein and diet alongside GLP-1 drugs

Lifestyle support is part of the tested condition, not an extra. REDEFINE 1, for example, gave every group lifestyle counseling on top of the study drug.

The cleanest trial of exercise plus a GLP-1 drug is S-LITE (New England Journal of Medicine, 2021). After an 8-week low-calorie diet, 195 Danish adults with obesity were randomized for a year. One group exercised, one took liraglutide 3.0 mg daily, one did both. A fourth got placebo. Compared with placebo, the combination group kept off 9.5 kg more weight, against 6.8 kg more for liraglutide alone, a gap that wasn't statistically significant. The fat-loss difference was clearer: the combination cut body-fat percentage about twice as much as either single strategy.

Lean mass is the main reason training and protein come up. In the BELIEVE trial described below, about 71% of the weight lost on semaglutide 2.4 mg alone was fat, so close to 30% came from lean tissue. A 2025 joint advisory from four US obesity and nutrition societies recommends resistance training and adequate protein during GLP-1 treatment. It notes that targets of 1.2-1.6 g of protein per kg of body weight per day have been proposed during active weight loss, and that using actual body weight can overestimate needs in people with obesity. Those are expert intake targets, not tested doses of any peptide.

Reduced appetite makes protein targets harder to hit; the appetite regulation page explains how these drugs curb hunger. Claims that some compounds raise energy expenditure are covered under thermogenesis.

Drugs added to protect muscle

A newer approach targets muscle directly. Myostatin and activin are signals that limit muscle growth, and antibodies that block them are being tested alongside semaglutide.

• Bimagrumab (BELIEVE, Phase 2, Nature Medicine 2026). In 507 adults with obesity, adding this antibody, given by IV infusion every 12 weeks, held lean-mass loss at 48 weeks to 0.8-2.3%, compared with 4.7-6.9% on semaglutide alone. In the high-dose combination group, 92.3% of the weight lost was fat, and at 72 weeks that group had lost 22.1% of body weight. Grip strength and patient-reported physical function didn't improve significantly.
• Trevogrumab (COURAGE, Phase 2, reported October 2026). Regeneron reported that trevogrumab at 25 or 75 mg, added to semaglutide 2.4 mg, limited lean-mass loss at 52 weeks to 5.8% and 4.2%, versus 7.3% with semaglutide alone. These lower doses didn't add weight loss.

This is the closest thing to evidence-backed "muscle-sparing synergy", and it is still Phase 2 with thin data on strength. As of October 2026 neither antibody is approved for obesity. WADA's 2026 Prohibited List bans myostatin and activin blockers, bimagrumab included, at all times for tested athletes.

User-reported stacks

Forums describe many combinations no trial has studied. A common one pairs a GLP-1 drug (often tirzepatide or gray-market retatrutide) with a growth hormone secretagogue, usually CJC-1295 with ipamorelin. The theory is that more growth hormone protects muscle during a calorie deficit. In a 2026 r/PeptidePathways thread asking for evidence on this pairing, nobody pointed to a study. One user reported good muscle retention on sermorelin plus tirzepatide alongside strength training, which can't separate the peptide from the training.

The evidence on the components is thin or negative:

• GH secretagogues have no human fat-loss outcome trials. In 2024 reviews for its compounding advisory committee, FDA found no articles on CJC-1295's effectiveness in humans with growth hormone deficiency, and the one Phase 2 trial of ipamorelin (for bowel recovery after surgery) didn't show effectiveness. Users in an r/Tesamorelin thread on adding tesamorelin to tirzepatide flagged the tension: growth hormone tends to push blood sugar up while GLP-1 drugs push it down. Tesamorelin is a prescription medicine, but its label covers only HIV-associated abdominal fat and says it isn't for weight loss management.
• AOD-9604 failed its human weight-loss trials. AOD-9604 is a modified version of the hGH 176-191 fragment. FDA's 2024 review found that in most human studies, oral or IV AOD-9604 didn't beat placebo; the largest, with 536 adults, missed its 12-week weight endpoint, and the developer ended work on obesity. FDA found no human data for injected use, which is how users take it.

Product quality is a separate risk. FDA has warned companies selling GLP-1 drugs, retatrutide among them, falsely labeled "for research purposes". It also says retatrutide and cagrilintide can't legally be used in compounding. For tested athletes, WADA's 2026 list doesn't include semaglutide or tirzepatide but does prohibit the GH secretagogues and AOD-9604.

What we still don't know

• Whether preserving lean mass with an add-on antibody improves strength or long-term health, not just scan results.
• Whether resistance training plus adequate protein protects muscle as well as those antibodies do. No trial has compared them head-to-head.
• How the FDA rules on CagriSema (expected late 2026) and whether retatrutide is submitted on schedule in early 2027.
• Whether any user stack built around a GH secretagogue changes body composition beyond a GLP-1 drug plus training. As of October 2026, nobody has tested it.